{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:50:55Z","timestamp":1761709855152,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clon.2021.05.009","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:17:32Z","timestamp":1623111452000},"page":"560-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adjuvant Therapy for High-risk Endometrial Carcinoma"],"prefix":"10.1016","volume":"33","author":[{"given":"J.","family":"Perera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2021.05.009_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2021.05.009_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2021.05.009_bib4","first-page":"419","article-title":"Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma","volume":"56","author":"Aalders","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clon.2021.05.009_bib5","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2021.05.009_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"9658","key":"10.1016\/j.clon.2021.05.009_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(08)61767-5","article-title":"ASTEC\/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis","volume":"373","author":"Blake","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2021.05.009_bib8","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/jnci\/djs374","article-title":"Adjuvant radiotherapy for stage I endometrial cancer; an updated Cochrane systematic review and meta analysis","volume":"104","author":"Kong","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9 Suppl. 3","key":"10.1016\/j.clon.2021.05.009_bib9","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/IGC.0000000000000264","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma","volume":"24","author":"Sagae","year":"2014","journal-title":"Int J Gynecol Cancer"},{"year":"2007","series-title":"Cancer of the corpus uteri. SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988\u20132001, patient and tumour characteristics. NCI, SEER program","author":"Kosary","key":"10.1016\/j.clon.2021.05.009_bib10"},{"key":"10.1016\/j.clon.2021.05.009_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clon.2021.05.009_bib12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clon.2021.05.009_bib13","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.05.009_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/bjc.2016.235","article-title":"L1CAM expression in endometrial carcinomas: an ENITEC collaboration study","volume":"115","author":"van der Putten","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2021.05.009_bib15","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2021.05.009_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/IGC.0000000000001187","article-title":"Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: an ENITEC collaboration study","volume":"28","author":"van der Putten","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2021.05.009_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.clon.2021.05.009_bib18","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2014.58.6693","article-title":"No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials","volume":"33","author":"Wiltink","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.05.009_bib19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clon.2021.05.009_bib20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2015.08.023","article-title":"Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 trial","volume":"93","author":"de Boer","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.05.009_bib21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.05.009_bib22","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2021.05.009_bib23","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3802\/jgo.2020.31.e22","article-title":"Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study","volume":"31","author":"\u00d8rtoft","year":"2020","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"Suppl","key":"10.1016\/j.clon.2021.05.009_bib24","article-title":"Postoperative chemotherapy or no further treatment for patients with node-negative stage I\u2013II intermediate or high risk endometrial cancer: the ENGOT-EN2\/DGCG trial","volume":"35","author":"Mirza","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.05.009_bib25","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer\u2014 results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clon.2021.05.009_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"24","author":"Randall","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.05.009_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2021.05.009_bib28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2021.05.009_bib29","first-page":"CD010681","article-title":"Adjuvant chemotherapy for advanced endometrial cancer","volume":"5","author":"Galaal","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2021.05.009_bib30","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2021.05.009_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clon.2021.05.009_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterization of 'multiple-classifier' endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J\u00a0Pathol"},{"issue":"12","key":"10.1016\/j.clon.2021.05.009_bib33","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int J Gynec Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:49:24Z","timestamp":1760543364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655521001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0936655521001862"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2021.05.009","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Therapy for High-risk Endometrial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2021.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}